About Protein FAM114A2
Protein FAM114A2 (FAM114A2) is a protein
from Homo sapiens identified by UniProt accession
Q9NRY5, 505 residues long.
MolForge cross-references it against 0 known binders and
37 disease associations.
Target properties
| Protein name | Protein FAM114A2 |
| UniProt accession | Q9NRY5 |
| Gene | FAM114A2 |
| Organism | Homo sapiens |
| Length | 505 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (37)
Diseases linked to this target (Open Targets).
- cancer · score 0.54
- Red cell distribution width · score 0.41
- apolipoprotein A 1 measurement · score 0.34
- self reported educational attainment · score 0.28
- body mass index · score 0.27
- lung adenocarcinoma · score 0.23
- sex hormone-binding globulin measurement · score 0.21
- breast adenocarcinoma · score 0.18
- lean body mass · score 0.16
- attempted suicide · score 0.12
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9NRY5-F1 | alphafold | PREDICTED | 66.08 | — |
Amino-acid sequence (505 residues)
MSDKDDIETP LLTEAAPILE DGNCEPAKNS ESVDQGAKPE SKSEPVVSTR KRPETKPSSD LETSKVLPIQ DNVSKDVPQT RWGYWGSWGK SILSSASATV ATVGQGISNV IEKAETSLGI PGPSEISTEV KYVAGETNAK ENENSSPVAG AFGVFSTIST AVQSTGKSVI SGGLDALEFI GKKTMDVIAE GDPGFKRTKG LMNRNATLSQ VLREAKEKEE IRTSNEVTVE TDKKTHYGLL FDEFQGLSHL EALEMLSQES EIKVKSILNS LSGEELETLK VELEQLKETF SLAEFCEEEE EEKKGDEDFT KDITELFSQL HVSSKPEKLA RARNTAHEWI RKSLTKPLAE NEEGEKQSEA ENTEQVNKNS IEDIHAFAIR SLAELTACSI ELFHKTAALV LHGRKQEVTA IERSQTLSQM TIVLCKELSS LSKEFTTCLT TAGVKEMADV LNPLITAVFL EASNSASYIQ DAFQLLLPVL EISLIENKIE SHRHELQGQK PLLEH
Explore Protein FAM114A2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets